Fig. 5.

In vivo antitumor activities of anti-CD105 CAR-T cells in the established subcutaneous human tumor xenografts. a Experimental schema: NOD/SCID mice were injected subcutaneously with Bel7404 cells (5 × 10⁵ cells/mouse). When the tumor volume reached about 100 mm³, the mice were randomized and treated with vehicle alone or with 2 × 10⁶ Utd, Mock, anti-CD19 CAR-T cells, and anti-CD105 CAR-T cells in 0.2 ml PBS (n = 6). b Bel7404 tumors from the mice killed at the endpoint. c The tumor weights were quantified. Anti-CD105 CAR-T cells significantly reduced the tumor weights. d The tumor growth curves. Anti-CD105 CAR-T cells significantly reduced the volumes of tumors. e The survival of tumor-bearing mice. Anti-CD105 CAR-T cells prolonged the survival of tumor-bearing mice. Data are representative images or expressed as the mean ± SD of each group